Mineralys Therapeutics Inc(MLYS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 5:21 PM ET (Korea 10/30 06:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.24 | Insider Own | 31.19% | Shs Outstand | 88.3M | Perf Week | -1.07% |
| Market Cap | 1.88B | Forward P/E | - | EPS next Y | 46.63% | Insider Trans | -1.67% | Shs Float | 60.8M | Perf Month | -15.48% |
| Enterprise Value | 1.31B | PEG | - | EPS next Q | -0.55 | Inst Own | 89.17% | Short Float | 12.23% | Perf Quarter | -16.77% |
| Income | -0.35B | P/S | - | EPS this Y | -95.79% | Inst Trans | 12.14% | Short Ratio | 6.25 | Perf Half Y | -20.3% |
| Sales | 0.00B | P/B | 3.41 | EPS next 5Y | 18.42% | ROA | -69.67% | Short Interest | 7.44M | Perf YTD | -41.47% |
| Book/sh | 6.24 | P/C | 2.84 | EPS past 3/5Y | -46.34% -101.68% | ROE | -80.88% | 52W High | -55.42% ($47.65) | Perf Year | -47.09% |
| Cash/sh | 7.48 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.9% | 52W Low | 5.57% ($20.12) | Perf 3Y | 179.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -19% | Gross Margin | - | Volatility(W/M) | 5.02% 5.63% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 34.46 | EPS Q/Q | -330.32% | Profit Margin | - | RSI (14) | 41.34 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 34.46 | Sales Q/Q | - | SMA20 | -1.8% ($21.63) | Beta | 0.7 | Target Price | $46.33 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/11/4 | SMA50 | -14.79% ($24.93) | Rel Volume | 1.75 | Prev Close | $21.38 |
| Employees | 76 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | -419.5% - | SMA200 | -21.53% ($27.07) | Avg Volume(3M) | 1.19M | Price | $21.24 |
| IPO | 2023/2/10 | Option/Short | Yes/Yes | Trades | 11344 | Volume | 2,077,173 | Change | -0.65% |
🧬 This is a US clinical-stage biotech company developing therapeutics for cardiovascular and metabolic diseases. It targets specific hormonal pathways to develop oral product candidates for treating uncontrolled hypertension and chronic kidney disease, and has a leading candidate in late-stage clinical development. It is a differentiated-mechanism cardiovascular and metabolic biotech aiming to address the significant unmet needs of large markets.
Over the past 1 year, on the lower side
55% below its 1-year high.
Traded more than usual. That is 175% of its average volume.
Next earnings report: November 4
5 days to go.
MLYS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -95.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be +179.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 89.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #112 of 594 in the industry
Based on market cap of $2B.
TRAX#110 First Tracks Biotherapeutics Inc $2B PER - 
COAG#111 Hemab Therapeutics Holdings Inc $2B PER - MLYS#112 Mineralys Therapeutics Inc $2B PER - 
ZBIO#113 Zenas Biopharma Inc $2B PER - 
NTLA#114 Intellia Therapeutics Inc $2B PER - 
FAQ
What kind of company is MLYS?
MLYS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MLYS?
The market cap of MLYS is approximately $1.9B, ranking 2,119 within its sector.
What is the 52-week high and low for MLYS?
MLYS has recorded a 52-week high of $47.65 and a low of $20.12.
